SHGA
ONCT

Sand Hill Global Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Sand Hill Global Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$42K – 164
2021
Q3 		$42K Hold
500
– – ﹤0.01% 156
2021
Q2 		$48K Hold
500
– – ﹤0.01% 160
2021
Q1 		$83K Buy
+500
New +$66.1K 0.01% 139

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

Sand Hill Global Advisors's ONCT Position: Q4 2021 in Review

Sand Hill Global Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2021, closing a stake of 500 shares — an estimated $42K sold.

Sand Hill Global Advisors first reported a position in ONCT in Q1 2021 and held it in 3 quarters. The position peaked at $83K in Q1 2021. 82 funds tracked by Wall St. Rank hold ONCT as of Q4 2021.

  • Sand Hill Global Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Sand Hill Global Advisors sold 500 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $42K.
  • Sand Hill Global Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Sand Hill Global Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $83K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Sand Hill Global Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.